Aaron Levine, PhD, MPhil, BS, Georgia Institute of Technology, Atlanta, GA, discusses the importance of addressing manufacturing and workforce challenges in order to drive the translation and commercialization of cell therapies. Given the increased complexity of cell-based therapies compared to other therapeutics, greater attention needs to be paid toward manufacturing and compliance with regulatory authorities before cell therapies can be produced on an industrial scale. Dr Levine also highlights the importance of building the cell therapy manufacturing workforce with education and training within the technical aspects of manufacturing, such as good manufacturing practice (GMP) compliance. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.
Aaron Levine’s work on ethical and policy issues related to cell therapy and cell manufacturing is supported, in part, by the U.S. National Science Foundation under Grant No. EEC-1648035. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the interviewee(s) and do not necessarily reflect the views of the National Science Foundation.